The immunomodulatory functions of DEXs have been extensively explored in preclinical cancer models, demonstrating their ability to stimulate CD8+ cytotoxic T lymphocytes (CTLs), polarize Th1 responses, and synergise with immune checkpoint inhibitors [13,23,24]. Here, CD8A is linked to cancer.